Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Europe Article
This is a selection made from among articles on Drug Treatment Europe. For a permanent link to this article, or to bookmark it for future reading, click here.
Pros and Cons of Drug Testing Your Employees in the Workplace
from: Drug testing employees in the workplace can be a valuable tool in detecting and putting a stop to drug use. Now, without further adieu, here are the pros and cons of drug testing your employees in the workplace. Pros of Drug Testing in the Workplace
Increases Safety: Drug testing in the workplace can make the working environment a much safer place to be.
Reduces Accidents: It has been noted that those under the influence of illicit substances are more likely to cause or be apart of accidents in the workplace. By drug testing, you eliminate or greatly reduce the incidence of accidents on the job.
Helps Drug Abusers: Many drug abusers are addicted to substances and need help. By enforcing drug testing in the workplace, you can catch someone’s drug problem before they further hurt themselves or others.
Cons of Drug Testing in the Workplace
Invasion of Privacy: Random drug testing in the workplace allows an employer the option of requiring a person to submit to drug tests if they wish to keep their jobs. Some consider this requirement to be an invasion of personal privacy and to be discriminatory against employees.
Costly: Drug testing can be quite an expensive endeavor, especially if you have a large company.
Could Be Unconstitutional: Along with being an invasion of privacy, drug testing in the workplace may be unconstitutional. While no rulings have been made on the subject as of yet, many groups feel random drug testing violates an individuals personal rights and freedoms.
About Author
This article is prepared by Christy Berger who writes for TestCountry.com . You can find a longer version of this article at Pros and Cons of Drug Testing Your Employees in the Workplace. The main resource of this article is the white paper at Creating a Drug Testing Program .
Source: ArticleTrader.com
Drug Treatment Europe Specific links
Drug Treatment Europe News
Drug Price Cuts in Top Five Countries of Europe - Tougher Reference Pricing Environment and Drug Price Freeze through ...
NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Drug Price Cuts in Top Five Countries of Europe - Tougher Reference Pricing ...
Read more...U.S. says drug abuse needs treatment, not just jail
LONDON (Reuters) - The United States sees drug abuse as a public health problem as much as a crime issue and is seeking to learn from countries in Europe and elsewhere about how to treat addiction as a disease, Barack Obama's drugs policy chief said on Tuesday. Gil Kerlikowske, the U.S. president's director of national drug control policy, said the United States is taking a more balanced ...
Read more...US says drug abuse needs treatment, not just jail
LONDON (REUTERS) - The United States (US) sees drug abuse as a public health problem as much as a crime issue and is seeking to learn from countries in Europe and elsewhere about how to treat addiction as a disease, President Barack Obama's drugs policy chief said on Tuesday. Related Stories Australian tycoon world's richest woman: report 5 aid workers kidnapped by unidentified gunmen in ...
Read more...New Drug Application for Regorafenib for the Treatment of Metastatic Colorectal Cancer Submitted by Bayer
SOUTH SAN FRANCISCO, Calif., May 23, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration ...
Read more...Arno Therapeutics Announces Orphan-Drug Designation for AR-42 in Europe
Arno Therapeutics, Inc. announced today that its investigational compound known as AR-42 has been granted orphan-drug designation by the European Medicines Agency’s Committee for Orphan Medicinal Products for the treatment of neurofibromatosis type 2 .
Read more...Bayer Submits New Drug Application for Regorafenib for the Treatment of Metastatic Colorectal Cancer
WAYNE, N.J., May 23, 2012 /PRNewswire/ --Â Bayer HealthCare announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the oral ...
Read more...Mixed Messages on Rare Disease Drug
An FDA advisory panel said a study of Vyndaqel for familial amyloid polyneuropathy did not provide proof of its benefit, but that proof may not be necessary.
Read more...Ariad CEO says Italy and Spain likely to pay for new cancer drug
Ariad Pharmaceuticals Inc. chief executive Harvey Berger said he’s confident Italy and Spain will reimburse the Cambridge-based drugmaker’s new cancer medicine and he plans to sell it there amid Europe’s debt crisis. Ariad plans to seek regulatory approval of the drug, called ponatinib, later this year for a cancer of the white blood cells known as chronic myeloid leukemia. The first phase of ...
Read more...Pozen migraine drug licensed to Desitin for commercialization in Europe
The migraine headache treatment developed by Pozen (NASDAQ:POZN) now has a partner for commercialization in Europe. Pozen licensed the compound MT 400 to German central nervous system therapies company Desitin in a deal that will pay the Chapel Hill, North Carolina drug developer $3 million up front, plus milestones and royalties from drug sales in the [...]
Read more...Research and Markets: Drug-eluting Stent Market in Europe 2011-2015
Dublin - Research and Markets has announced the addition of the "Drug-eluting Stent Market in Europe 2011-2015
Read more...